Tanfanercept is under clinical development by HanAll Biopharma and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tanfanercept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
Tanfanercept overview
Tanfanercept (HL-036) is under development for the treatment of dry eye. It is a molecularly engineered soluble human TNF receptor I fragment of Enbrel. The drug candidate is administered orally and through ophthalmic route. It is a biobetter and acts on tumor necrosis factor alpha (TNF-a). It is based on resistein technology. It was also under development for rheumatoid arthritis (RA), age-related macular degeneration and uveitis.
HanAll Biopharma overview
HanAll Biopharma (HanAll), formerly HanAll Pharmaceutical, is a developer of generic and specialty drugs for treatment of diseases related to digestive, endocrine, musculoskeletal and urinary system. The company’s pipeline products include HL036, a drug being developed for treating dry eye diseases; HL189 against non-infectious uveitis; IM156 targeting cancers; and HL190 to treat wet age-related macular degeneration. It also sells drugs for treating digestive dysfunction, osteoporosis, liver dysfunction, hepatic coma, metabolic disorders caused due to hypocalcemia, tetania, bone pain and also bone lesions. HanAll also conducts research for developing drugs in the therapeutic areas of autoimmune, eye diseases and immuno oncology indications. The company works in partnership with global pharmaceutical companies and academic institutions for advancing its pipeline products. It has operations in South Korea and the US. HanAll is headquartered in Seoul, South Korea
For a complete picture of Tanfanercept’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
